Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 19, 2025 03:40 ET | Source: Teva Pharmaceutical Industries Ltd

Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea®

According to the settlement agreement, the proposed biosimilar to Eylea® (aflibercept) can be marketed in the U.S., if approved by the FDA, in the fourth quarter of 2026, or earlier under certain...
February 12, 2025 04:57 ET | Source: Research and Markets

Eylea (Aflibercept) Market Research Report 2025: Strategic Partnerships and Biosimilars Enhance Accessibility, Diabetes-Related Retinal Issues and Myopia Surge Boost - Long-term Forecasts to 2033

Dublin, Feb. 12, 2025 (GLOBE NEWSWIRE) -- The "Eylea Market Opportunities and Strategies to 2033" report has been added to ResearchAndMarkets.com's offering.This report describes and explains the...
February 23, 2024 07:32 ET | Source: Research and Markets

Aflibercept (Eylea) Biosimilars Pipeline Review 2024: Patents are Due to Run out from 2023 to 2032

Dublin, Feb. 23, 2024 (GLOBE NEWSWIRE) -- The "Aflibercept (Eylea) Biosimilars Pipeline Review" report has been added to ResearchAndMarkets.com's offering.This product provides basic information on...
February 08, 2024 15:17 ET | Source: Spherix Global Insights

Stakes Are High for Regeneron's Eylea HD as Genentech's Vabysmo Continues to Gain Momentum, Prompting Doctors to Weigh Their Options Between Two Industry Titans, According to Spherix Global Insights

Exton, Pennsylvania, Feb. 08, 2024 (GLOBE NEWSWIRE) -- As Age-Related Macular Degeneration (AMD) Awareness Month unfolds, illuminating the visual challenges faced by millions of Americans with AMD,...
January 08, 2024 09:45 ET | Source: Curative Biotechnology, Inc. 

Curative Biotechnology, Inc. Announces Nomination of Dr. Theresa Heah to Board of Directors

Appointment of Independent Director Nominee to become effective upon approval by and listing of common stock on a National Exchange Boca Raton, FL, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Curative...
November 01, 2023 14:55 ET | Source: Spherix Global Insights

Rate of Switching from Regeneron’s Eylea to Genentech’s Vabysmo Doubled Over Past Year for Diabetic Macular Edema

Exton, Pennsylvania, Nov. 01, 2023 (GLOBE NEWSWIRE) -- As U.S. ophthalmologists increasingly embrace a wider array of treatment options, the landscape of the diabetic macular edema (DME) market has...
July 25, 2023 05:23 ET | Source: Research and Markets

Global Eylea Market to Reach $9.33 Billion by 2027, Driven by Increasing Prevalence of Ocular Diseases

Dublin, July 25, 2023 (GLOBE NEWSWIRE) -- The "Eylea Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering. This report provides strategists, marketers, and senior...
December 20, 2022 08:10 ET | Source: Persistence Market Research

Anti-Vascular Endothelial Growth Factor Therapeutics market is expected to reach a US$13.1 Bn by 2032 at a CAGR 1% | According PMR

New York, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Anti-Vascular Endothelial Growth Factor Therapeutics market is expected to reach a US$ 455 Mn by 2032 at a CAGR 1% | According PMR Anti-Vascular...
June 03, 2022 06:58 ET | Source: Research and Markets

The Worldwide Anti-Vascular Endothelial Growth Factor Therapeutics Industry is Expected to Reach $13.3 Billion by 2030

Dublin, June 03, 2022 (GLOBE NEWSWIRE) -- The "Anti-Vascular Endothelial Growth Factor Therapeutics Market Share, Size, Trends, Industry Analysis Report, By Product; By Disease; By Region; Segment...
July 26, 2016 07:30 ET | Source: Clearside Biomedical, Inc.

Clearside Biomedical, Inc. Announces Patient Treatment Comparison from the Phase 2 Trial (TANZANITE) in Patients with Macular Edema Associated with Retinal Vein Occlusion

78% of Patients Required No Additional Treatment in the Trial Arm with Concomitant Suprachoroidally Administered Zuprata™ and Intravitreally Administered Eylea®Patients Reached an Average BCVA...